Tranilast, an anti-allergic drug, possesses antagonistic potency to angiotensin II

European Journal of Pharmacology

Volumn 361, Issue 2-3, 1998, Pages 199-205

  Jin, Denan ^a   Takai, Shinji ^a   Shiota, Naotaka ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin II receptor; Azelastine; Disodium cromoglycate; Pemirolast; Tranilast; Vessels, human

Indexed keywords

ANGIOTENSIN; ANTIALLERGIC AGENT; AZELASTINE; CANDESARTAN; CROMOGLYCATE DISODIUM; NORADRENALIN; PEMIROLAST; POTASSIUM CHLORIDE; TRANILAST;

ADULT; AGED; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GASTROEPIPLOIC ARTERY; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASOCONSTRICTION;

ADRENERGIC ALPHA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II; ANIMALS; ANTHRANILIC ACIDS; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; AORTA; ARTERIES; CROMOLYN SODIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTAMINE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; NOREPINEPHRINE; POTASSIUM CHLORIDE; PYRIDINES; PYRIMIDINONES; RABBITS; RECEPTORS, ANGIOTENSIN; VASOCONSTRICTION;

EID: 0032553703     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00740-7     Document Type: Article

References (30)

1. Azuma H., Banno K., Yoshimura T. Pharmacological properties of N-(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′), a new anti-atopic agent. Br. J. Pharmacol. 58:1976;483-488.
2. Cox J.S. Disodium cromoglycate (FPL 670) ('Intal'): a specific inhibitor of reaginic antibody-antigen mechanisms. Nature. 216:1967;1328-1329.
3. Ferns G.A., Raines E.W., Sprugel K.H., Motani A.S., Reidy M.A., Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by antibody to PDGF. Science. 253:1991;1129-1132.
4. Fischer B., Schmutzler W. Inhibition by azelastine of the immunologically induced histamine release from isolated guinea pig mast cells. Arzneim-Forsch./Drug Res. 31:1981;1193-1195.
5. Geisterfer A.A., Peach M.J., Owens G.K. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ. Res. 62:1988;749-756.
6. Gould C.A., Ollier S., Aurich R., Davies R.J. A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness. Br. J. Clin. Pharmacol. 26:1988;515-525.
7. Hasegawa T., Takagi K., Nadai M., Ogura Y., Nabeshima T. Kinetic interaction between theophylline and a newly developed anti-allergic drug, pemirolast potassium. Eur. Clin. Pharmacol. 46:1994;55-58.
8. Isaji M., Nakajoh M., Naito J. Selective inhibition of collagen accumulation by N-(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′) in granulation tissue. Biochemical Pharmacology. 36:1987;469-474.
9. Itoh H., Mukoyama M., Pratt R.E., Gibbons G.H., Dzau V.J. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J. Clin. Invest. 91:1993;2268-2274.
10. Jin D., Song K., Oka Y., Takai S., Shiota N., Miyazaki M. Pharmacological profiles of a novel non-peptide angiotensin II type I receptor antagonist HR720 in vitro and in vivo. Jpn. J. Pharmacol. 75:1997;259-266.
11. Komatsu H., Kojima M., Tsutsumi N., Hamano S., Kusama H., Ujiie A., Ikeda S., Nakazawa M. Study of the mechanism of inhibitory action of tranilast on chemical mediator release. Jpn. J. Pharmacol. 46:1988;43-51.
12. Lee H.K., Ohya Y., Doupnik C.A., Sperelakis N. Effects of azelastine on contraction of guinea pig tracheal smooth muscle. Eur. J. Pharmacol. 187:1990;67-74.
13. Lindner V., Reidy M.A. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA. 88:1991;3739-3743.
14. Liu M.W., Roubin G.S., King S.B. III Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation. 79:1989;1374-1387.
15. Macleod D.C., Strauss B.H., de Jong M., Escaned J., Umans V.A., van Suylen R.J., Verkerk A., de Feyter P.J., Serruys P.W. Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J. Am. Coll. Cardiol. 23:1994;59-65.
16. Masuo M., Shimada T., Kitazawa T. Mechanism of inhibitory effects of azelastine on smooth muscle contraction. J. Pharmacol. Exp. Ther. 260:1992;1300-1308.
17. Okuda Y., Adrogue H.J., Nakajima T., Mizutani M., Asano M., Tachi Y., Suzuki S., Yamashita K. Increased production of PDGF by angiotensin and high glucose in human vascular endothelium. Life Sci. 59:1996;1455-1461.
18. Osterrieder W., Muller R.K., Powell J.S., Clozel J.P., Hefti F., Baumgartner H.R. Role of angiotensin II in injury-induced neointima formation in rats. Hypertension. 18:1991;II60-II64. (Suppl. 4).
19. Powell J.S., Clozel J.P., Muller R.K., Kuhn H., Hefti F., Hosang M., Baumgartner H.R. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 245:1989;186-188.
20. Powell J.S., Muller R.K., Nat D., Baumgartner H.R. Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors. J. Am. Coll. Cardiol. 17:1991;137B-142B.
21. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J. Am. Coll. Cardiol. 28:1996;803-812.
22. Shibouta Y., Inada Y., Ojima M., Wada T., Noda M., Sanada T., Kubo K., Kohara Y., Naka T., Nishikawa K. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylate (TCV-116). J. Pharmacol. Exp. Ther. 266:1993;114-120.
23. Suzawa H., Kikuchi S., Arai N., Koda A. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keroid fibroblasts. Jpn. J. Pharmacol. 60:1992;91-96.
24. Tanaka K., Honda M., Kuramochi T., Morioka S. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis. 107:1994;179-185.
25. The TREAT Study Investigators The impact of tranilast on restenosis following coronary angioplasty: the Tranilast Restenosis Following Angioplasty Trial (TREAT). Circulation. 90:1994;I-652.
26. Timmermans P.B., Carini D.J., Chiu A.T., Duncia J.V., Price W.A. Jr., Wells G.J., Wong P.C., Johnson A.L., Wexler R.R. The discovery of a new class of highly specific nonpeptide ngiotensin II receptor antagonists. Am. J. Hypertens. 4:1991;275S-281S.
27. Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carini D.J., Lee R.J., Wexler R.R., Saye J.A., Smith R.D. Agiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45:1993;205-251.
28. Van Rossum J.M. Cumulative dose-response curves. Arch. int. Pharmacodyn. 143:1963;299-330.
29. Yanagihara Y., Kasai H., Matsui S., Ninomiya K. Immunopharmacological studies on TBX, a new antiallergic drug: 3. Inhibitory effects on histamine release from lung fragments and bronchoconstriction in guinea pigs. Jpn. J. Pharmacol. 51:1989;83-92.
30. Yanagihara Y., Kasai H., Shida T. Immunopharmacological studies on TBX, a new antiallergic drug: 2. Inhibitory effects on histamine release from peritoneal mast cells and lung fragments. Jpn. J. Pharmacol. 48:1988;103-112.